Intradermal LPS and Antibiotics

Inflammation; Skin Clinical Trial

Official title: Investigating Anti-inflammatory Effects of Topical Antibiotics in an LPS Skin Challenge Model

Status Completed

Clinical Trial Summary

Erythromycin and clindamycin are believed to have anti-inflammatory aspects. This study investigates the possible anti-inflammatory effects of erythromycin and clindamycin.

Clinical Trial Description

Convincing mechanistic reports on the immunomodulatory action of erythromycin and clindamycin are scarce, rarely based on experiments in freshly isolated human immune cells, and potentially contradicting. Moreover, direct immunomodulatory effects of both antibiotics have never been demonstrated in vivo. The Centre for Human Drug Research Biomarker lab has studied in depth the immunomodulatory actions of erythromycin and clindamycin in vitro. These in vitro experiments on primary human immune cells demonstrated that both erythromycin and clindamycin are able to modulate the immune response of peripheral blood mononuclear cells upon stimulation with different immune triggers such as lipopolysaccharide (LPS) and polyI:C. In this current study the in vitro work will be translated to an in vivo study where it will be made into an intradermal LPS skin challenge model in healthy volunteers. ;

Related Conditions & MeSH terms

• Dermatitis
• Inflammation
• Inflammation; Skin

• NCT number: NCT03779360
• Study type: Interventional
• Source: Centre for Human Drug Research, Netherlands
• Status: Completed
• Phase: N/A
• Start date: October 12, 2018
• Completion date: February 23, 2019